NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of XBiotech, Inc. (NASDAQ:XBIT) resulting from allegations that XBiotech may have issued materially misleading business information to the investing public.
On November 23, 2015, XBiotech disclosed after-hours that data for 72 patients in its study of True Human(TM) therapeutic antibodies have been compromised and are not available for primary endpoint evaluation due to irregularities. These irregularities include patients: (1) dropping off the study prior to receiving any dosing with drug or placebo; (2) erroneously receiving either placebo or study drug; and (3) failing to receive scheduled DEXA scans, properly complete EORTC evaluation, or both. On this news, shares of XBiotech fell sharply during after-hours trading on November 23, 2015, damaging investors.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by XBiotech investors. If you purchased shares of XBiotech on or before November 23, 2015, please visit the firm’s website at http://rosenlegal.com/cases-791.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
